Cloverleaf Bio

Early-stage therapeutics company developing engineered tRNA-based RNA therapeutics for cancer

Biotech & Life Sciences

Sector

Biotechnology drug development

Model

01Company Overview

Early-stage therapeutics company developing engineered tRNA-based RNA therapeutics for cancer. Its platform selectively and durably inhibits multiple RNA-modifying enzymes that cancer cells depend on.

02Backed By1 investor

4C4BIO Capital→

03Recent Activity

Is this your company? Claim your profile

FROM 4BIO Capital

4BIO Capital led an upsized and oversubscribed $33M seed round in Cloverleaf Bio, an RNA therapeutics company developing engineered tRNA-based cancer therapeutics. Strategic investors include AbbVie Ventures, Eli Lilly, and Boehringer Ingelheim Venture Fund.